SWOG clinical trial number
30904
A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma
Closed
Phase
Published
Research committees
Genitourinary Cancer
Eligibility Criteria Expand/Collapse
Pt must have solitary T1-T2 renal tumors, suspicious for renal adenocarcinoma in the presence of a normal contralateral kidney. Tumor must be well located so that surgery can be safely done in healthy tissue; should not exceed 5 cm in diameter; must be single on CT scan; does not show evidence of invasion of the perirenal fat (T1-T2) on CT or IVU. Pt must have N0, M0 disease, be fit for surgery with a WHO performance status of less than 2. Pt must not have a solitary kidney, von Hippel-Lindau disease, multifocal disease, T3-T4 tumors, clinical presence of distant or lymphatic mets nor a WHO performance status of greater than 2.
Publication Information Expand/Collapse
2014
PMid: PMID23850254 | PMC number: not available
Other Clinical Trials
SWOG Clinical Trial Number
S2312
A Phase III Study of Cabazitaxel with or without Carboplatin in Patients with metastatic castrate-resistant prostate cancer (mCRPC), Stratified by Aggressive Variant Signature
Research Committee(s)
Genitourinary Cancer
Activated
09/03/2024
Accrual
0%
Open
Phase
SWOG Clinical Trial Number
S2210
S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"
Research Committee(s)
Genitourinary Cancer
Activated
08/14/2023
Accrual
7%
Open
Phase
SWOG Clinical Trial Number
S2200
S2200, A Phase II Randomized Trial of Cabozantinib with or Without Atezolizumab in Patients with Advanced Papillary Renal Cell Carcinoma: PAPMET2
Research Committee(s)
Genitourinary Cancer
Activated
09/19/2022
Accrual
14%
Open
Phase